Iomab-B (I-131-apamistamab) / Actinium, Immedica 
Welcome,         Profile    Billing    Logout  
 2 Diseases   1 Trial   1 Trial   387 News 


123»
  • ||||||||||  Iomab-B (I-131-apamistamab) / Actinium, Immedica
    131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML (Stars at Night B2 & B3 (Ballroom Level, Henry B. Gonzalez Convention Center); in-person) -  Dec 5, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_720;    
    P3
    Both PIF and TP53 for Iomab B pts were double in frequency compared to the CC patients. Iomab-B was effective in improving outcomes despite advancing age and presence of these very high-risk features.
  • ||||||||||  Iomab-B (I-131-apamistamab) / Actinium, Immedica
    131I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_2597;    
    P3
    Pts with R/R AML who have multiple risk factors such as adverse risk cytogenetics, age >65, venetoclax failure, high comorbidity index or poor KPS are typically not considered for alloHCT due to high transplant-related mortality and post-transplant relapse rates. 131 I-apamistamab was effective in achieving durable responses in R/R AML pts irrespective of the presence of multiple risk factors and successfully enabled alloHCT in such pts due to its targeted mechanism of action.
  • ||||||||||  Iomab-B (I-131-apamistamab) / Actinium, Immedica, briquilimab (JSP191) / Jasper Therap
    DEBATE: Should Patients with AML and Active Disease be Transplanted?: CON (LEVEL 3, GENERAL ASSEMBLY) -  Jun 21, 2023 - Abstract #SOHO2023SOHO_255;    
    Recent prospective data from the phase III ASAP Trial also suggest that in patients with poor response after initial first induction therapy or relapsed AML watchful waiting and sequential conditioning prior to allogeneic HCT result in comparable CR rates as could be observed with salvage chemotherapy with high-dose cytarabine plus anthracycline...Early HLA-typing of AML patients and their family members (possibly at the time of diagnosis), conditioning regimens incorporating novel agents, such as briquilimab or 131I-apamistamab, engineered donor grafts and maintenance therapy with novel agents or cell therapeutics have the potential to improve disease-free and overall survival in this patient population through improved disease control...Allogeneic HCT should be considered in this patient population, preferably in the context of a clinical trial testing novel treatment modalities. Updated prognostic score systems have the potential to identify subgroups of patients deriving the most benefit from these approaches.
  • ||||||||||  Iomab-B (I-131-apamistamab) / Actinium, Immedica
    Journal:  Nelson Bay Reovirus Isolated from Bats and Blood-Sucking Arthropods Collected in Yunnan Province, China. (Pubmed Central) -  Jun 12, 2023   
    This study successfully isolated two NBV strains (MLBC1302 and MLBC1313) from blood-sucking bat fly specimens (Eucampsipoda sundaica) and one (WDBP1716) from the spleen specimen of a fruit bat (Rousettus leschenaultii), which were collected at the China-Myanmar border area of Yunnan Province...While the potential threat to humans remains to be determined, evolutionary analyses involving different segments revealed that the novel strains had complex reassortment histories, with S1, S2, and M1 segments highly similar to human pathogens. Further experiments are required to determine whether more NBVs are vectored by bat flies, their potential threat to humans, and transmission dynamics.
  • ||||||||||  Iomab-B (I-131-apamistamab) / Actinium, Immedica
    An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (Hall D (Ernest N. Morial Convention Center)) -  Nov 4, 2022 - Abstract #ASH2022ASH_6475;    
    P1
    Within the last year alone, the FDA approved brexu-cel for adults w/ R/R B-ALL and expanded indications for liso-cel and axi-cel to include DLBCL w/ primary refractory disease or early first relapse...Anti-cytokine therapies beyond tocilizumab (anti-IL-6R mAb) are being investigated for prevention of CRS/ICANS, including lenzilumab (anti-GM-CSF mAb) and anakinra (IL-1R antagonist)...Accordingly, we designed and initiated a pilot study of Iomab-B w/ adoptive cellular therapy (Iomab-ACT; Fig 1A).Study design and Iomab-ACT is a single-institution pilot study of Iomab-B (w/o chemotherapy) as conditioning prior to 19-28z CAR-T in adults w/ R/R B-ALL or DLBCL (NCT04512716)...Unexpected toxicity (given low dose of ARC) observed in 1 pt included severe trilineage cytopenias lasting >8 wks (requiring RBC/PLT transfusion support, G-CSF, romiplostim) w/o marrow hypoplasia and w/o other apparent neoplastic or drug-induced etiology; this met criteria for dose-limiting toxicity and we will monitor in the next 3 pts...Key exploratory objectives include describing changes in circulating immune cells following ARC and 19-28z CAR T-cells w/spectral cytometry using a custom antibody panel (Fig 1B) and cytokine levels in cerebrospinal fluid. We hope to generate preliminary data to guide further study of CD45-targeted ARCs prior to CAR-T and other forms of adoptive cellular therapy.
  • ||||||||||  Zamyl (lintuzumab) / Seagen, Iomab-B (I-131-apamistamab) / Actinium, Immedica, Actimab-A (lintuzumab-Ac225) / Actinium
    Journal:  Where do we stand with radioimmunotherapy for acute myeloid leukemia? (Pubmed Central) -  Apr 28, 2022   
    P3
    A first anti-AML RIT may soon become available. This might propel further work to develop RIT-based treatments for AML, with many such efforts already ongoing.